pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

Nabla executive Alex LeBrun discusses ‘world model’ AI as an alternative to large language models

Jul 22, 2026·read at STAT ↗Neutral

Brittany Trang of STAT’s AI Prognosis newsletter interviewed Alex LeBrun, the executive chairman of AI scribe company Nabla, to explore a concept called a “world model.”

LeBrun described a world model as a system that builds an internal representation of its environment, allowing it to predict outcomes without relying on the massive text datasets that power typical large language models.

The conversation also touched on growing concerns about privacy, noting that people are increasingly recording everyday interactions without consent, a trend highlighted by recent media coverage.

The interview is part of a subscriber‑only feature on STAT+, requiring a paid subscription to access the full content.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What is a ‘world model’? Nabla’s Alex LeBrun explains”

read at STAT ↗
459 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
DisPATCH

related stories

  • 3d agoSTAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and moreSTAT
  • Aug 5STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AISTAT
  • Jul 29STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicatedSTAT
  • Jul 15STAT+: The whistleblower, The Lab, and the fine printSTAT
  • Jul 14The risk of refusing a newborn’s vitamin K shotSTAT